Condition
Antipsychotics
Total Trials
5
Recruiting
2
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 4 (1)
Trial Status
Completed3
Recruiting2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06251635Not ApplicableRecruiting
Effects of Antipsychotics on Brain Insulin Action in Females
NCT06049953RecruitingPrimary
Maternal And Infant Antipsychotic Study
NCT03376763Phase 4Completed
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
NCT01562808Not ApplicableCompletedPrimary
Change in Brain Metabolism and Cognitive Function by Aripiprazole
NCT00937755Completed
The Study of Atypical Antipsychotics-induced Metabolic Disturbances
Showing all 5 trials